🔊CEOInterviews

Jason Carroll on leadership

From When Your Strengths Get Too Loud | Jason Carroll | TEDxJesterCirED · · TEDx Talks

“Think about the strength of a natural leader... but what happens when the leadership volume knob gets turned up too high? We've all seen this: the leader becomes the controller.”

Jason Carroll
Cofounder, Hudson River Trading
leadershippersonal development

On , Jason Carroll, Cofounder at Hudson River Trading, spoke about leadership during When Your Strengths Get Too Loud | Jason Carroll | TEDxJesterCirED on TEDx Talks.

When Your Strengths Get Too Loud | Jason Carroll | TEDxJesterCirED
Watch on YouTube
When Your Strengths Get Too Loud | Jason Carroll | TEDxJesterCirED
TEDx Talks
Watch on YouTube
What if your greatest strengths—those traits that got you praised, promoted, and picked first—are the very things holding you back ...
Jason Carroll

About Jason Carroll

Cofounder · Hudson River Trading

Jason Carroll, CEO and Executive Director of Entropy Neurodynamics, discussed the company's progress in psychedelic drug delivery during a May 2026 interview. He described the company's approach as delivering a precise IV infusion of psilocin, the active ingredient in psilocybin, which he said offers more control and less variability compared to oral psilocybin. Carroll highlighted recent clinical results for the compound TRP 803 in treating irritable bowel syndrome, presented at a major gastroenterology conference by researchers from Massachusetts General Hospital and Columbia University. He stated the results showed a 75% responder rate in a treatment-resistant group, which he described as the strongest result of any IBS therapy. Carroll outlined upcoming milestones, including data from a binge eating disorder study expected in July and a second cohort in the fourth quarter of 2026. He also said the company is close to announcing a parallel study involving over 60 patients across multiple indications, which he described as the most significant study of its kind in psychiatry. He noted that the company's primary focus remains psychiatry, but the IBS results provide a potential parallel approval pathway through gastroenterology.

Profile compiled from Jason Carroll's verified public interviews and appearances. See all quotes & transcripts →

More from Jason Carroll Full Transcript Explore All Executives